Articles

• Forecasting for orphan drugs: The data challenge

  Gianclaudio Floria, senior manager for business planning and analysis at Amgen, on best practice in forecasting for orphan drug development.

  (Jul 8, 2010)
• Designing adherence programs: Local is better than global

  Kenneth Youngstein, CEO of Biocom, on the regulatory, strategic, and tactical challenges of cross-border compliance programs.

  (Aug 23, 2010)
• Will big pharma become a collection of marketing and distribution firms?
  (Oct 5, 2010)
• Personalized medicine: A kick-start for innovation?

  *Angelo DePalma reports on how personalized medicine may further weaken the blockbuster model of drug development but open up lucrative new niche markets*

  (Dec 8, 2010)
• How to build value through comparative effectiveness research
  (Jan 17, 2011)
• Patent expiration: Innovate or die

  *Pharma is unprepared for the blockbuster patent expirations due over the next few years. Angelo DePalma argues that innovation is the only strategic solution*

  (Feb 3, 2011)
• Marketing, patient data, and privacy concerns

  *Anonymous patient-level data (APLD) is an attractive information source for pharma marketers, but its acquisition and use are complex.*

  (Feb 14, 2011)
• New models for drug discovery and marketing

  Angelo DePalma investigates how emerging collaborative partnerships could alter how drug firms manage innovation and market new medicines

  (Jun 5, 2011)
• Branded generics: The emerging market opportunity

  Pharma firms are betting that branded generics will become a powerful source of revenue, particularly in emerging markets. Angelo DePalma reports

  (Jul 4, 2011)
• Forecasting the pain management market

  Angelo DePalma outlines the prospects for the global market for pain management pharmaceuticals and devices

  (Jul 26, 2011)
• 1
• 2
• Next
• Last

History

Member for

1 year 32 weeks